New fertility drug development techniques by Organon
In the 7th International Symposium on GnRH Analogs in Cancer and Human Reproduction,
Organon presented new techniques of development of fertility drugs.
Organon scientists have succeeded in customizing the follicle-stimulating hormone(FSH) molecule by adding a hybrid subunit, which extends FSH's active life. This was achieved through an international collaboration. This longer active life will me...
Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in
Phase III Pivotal Trial as Compared to Neostigmine
OSS, The Netherlands, June 11, 2007 /PRNewswire/ -- Sugammadex -the novel selective relaxant binding agent (SRBA) being developedby
Organon, the human healthcare business unit of Akzo Nobel -demonstrated in a Phase III pivotal trial a 9-12 times fasterreversal of neuromuscular blockade as compared to neostigmine,without evidence of post operative residual curarization (PORC) orre-occurre...
Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in
Phase III Pivotal Trial Compared to Neostigmine
OSS, the Netherlands, June 11, 2007-Sugammadex - the novelselective relaxant binding agent (SRBA) being developed by
Organon,the human healthcare business unit of Akzo Nobel - demonstrated ina Phase III pivotal trial a 9-12 times faster reversal ofneuromuscular blockade as compared to neostigmine, without evidenceof post operative residual curarization (PORC) or re-occurrence ofmuscle relax...
Organon's Asenapine Effective in a Phase III Study for the
Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA
Meeting
SAN DIEGO, May 21, 2007 /PRNewswire/ -- Asenapine -- aninvestigational drug being developed by
Organon, the humanhealthcare business unit of Akzo Nobel, for bipolar I disorder andschizophrenia -- was demonstrated to be more effective than placeboin treating acute manic and mixed episodes associated with bipolarI disorder, according to new Phase III results, from a studypresented at the A...